Last reviewed · How we verify
Detect and visualize lesions with abnormal vascularity with MRI — Treatment Landscape & Competitive Intelligence
2 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Elucirem | GADOPICLENOL | Guerbet | 2022-01-01 | |||
| Elucirem | Elucirem | Guerbet |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Guerbet · 2 drugs in Detect and visualize lesions with abnormal vascularity with MRI
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Detect and visualize lesions with abnormal vascularity with MRI:
- Detect and visualize lesions with abnormal vascularity with MRI treatment updates — RSS
- Detect and visualize lesions with abnormal vascularity with MRI treatment updates — Atom
- Detect and visualize lesions with abnormal vascularity with MRI treatment updates — JSON
Cite this brief
Drug Landscape (2026). Detect and visualize lesions with abnormal vascularity with MRI — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/detect-and-visualize-lesions-with-abnormal-vascularity-with-mri. Accessed 2026-06-10.
Related
- Detect and visualize lesions with abnormal vascularity with MRI full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing